1. FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma.
- Author
-
Fu, Kaili, Pang, Yizhen, Zhao, Liang, Lin, Limei, Wu, Hua, Sun, Long, Lin, Qin, and Chen, Haojun
- Subjects
RADIOISOTOPE therapy ,THERAPEUTIC use of monoclonal antibodies ,NASOPHARYNX cancer ,PATIENT aftercare ,DISEASE progression ,PROTEOLYTIC enzymes ,LABORATORIES ,DISEASE relapse ,RADIONUCLIDE imaging ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,DEOXY sugars ,COMPUTED tomography ,DEATH - Abstract
The article describes the case of a 25-year-old man who was diagnosed with non-keratinizing undifferentiated nasopharyngeal carcinoma (T2N3M0) in July 2019. Topics covered include the medical history of the patient, patient outcome after receiving the experimental therapy, fibroblast activation protein (FAP)-targeted radionuclide therapy, and the potential feasibility of FAPI-46 in the treatment of metastatic nasopharyngeal carcinoma as demonstrated by the case.
- Published
- 2022
- Full Text
- View/download PDF